丙肝治疗资料课件.ppt

* * 中国80％以上的丙肝患者为基因1b型，如果无法进行基因分型，建议按照基因1型进行治疗。 * * * ML 17131, Ferenci * * * * * Slide 27. Study designs: summary The study by Berg and colleagues compared treatment of genotype 1 patients randomised at baseline to receive PEGASYS? 180 μg/wk plus COPEGUS? 800 mg/day for 48 weeks (n=230) versus 72 weeks (n=225).1 The study by Sánchez-Tapias et al involved 510 patients treated with PEGASYS? 180 μg/wk plus COPEGUS? 800 mg/day. The 326 patients who did not achieve an RVR at week 4 were randomized to receive 48 weeks or (n=165) or 72 weeks (n=161) of treatment.2 Those patients who achieved an RVR were randomised to receive 24 or 48 weeks’ treatment, depending on genotype and viral load.2 The study by Ferenci and colleagues compared treatment of genotype 1/4 patients treated with PEGASYS? 180 μg/wk plus COPEGUS? 1000/1200 mg/day.3 Patients were randomized to one of four treatment groups according to their virological responses at weeks 4 and 12. Patients with an RVR at week 4 were assigned treatment for a further 20 weeks, whilst all other patients continued therapy and were reassessed at week 12. Those with 600 IU/mL or ≥2 log10 drop in HCV RNA at week 12 were randomized to receive treatment for a total of 48 or 72 weeks, whilst those with 600 IU/mL or ?2 log10 drop in HCV RNA at week 12 were treated for a total of 72 weeks.3 1. Berg T, et al. Gastroenterology 2006; 130: 1086 2. Sánchez-Tapias J, et al. Gastroenterology 2006; 131: 451 3. Ferenci P, et al. 57th AASLD 2006; Abstract 390 * Slide 30. Consistent improvement with 72 weeks’ therapy in G1 patients with a partial EVR Conversely, 72 weeks’ treatment of genotype 1 patients with a pEVR (defined as no RVR and 2 log10 drop but HCV RNA 50 IU/mL at week 12) consistently improved SVR rates compared with those observed with the standard duration of 48 weeks. Sánchez-Tapias JM, et al. APASL 2007; Abstract 0-196 * Slide *. Optimising outcomes in genotype 1/4 * * * * * Slide 48: Benefit from intensification of tre